|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.
|
17006983 |
2006 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
COX-2 is overexpressed in 50% of benign polyps and 80-85% of adenocarcinomas.
|
10630643 |
1999 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
COX-2 mRNA was assayed in both gastric cancer cell lines and biopsy specimens from 37 gastric adenocarcinomas, five gastric adenomas, and five hyperplastic polyps by reverse transcription-polymerase chain reaction.
|
11223821 |
2001 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
COX-2 RNA expression was confirmed in various grades of adenocarcinoma by ribonuclease protection assay.
|
11592775 |
2001 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Cyclooxygenase-2 (COX-2) is a crucial enzyme in the conversion of arachidonic acid to prostaglandin E2 (PGE(2)) and is significantly upregulated in many types of adenocarcinomas.
|
15033780 |
2003 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
|
16521222 |
2006 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
|
16521222 |
2006 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
COX-2 was expressed in 14.3% of normal gallbladder epithelium, 70.3% of dysplastic epite hlium, and 59.2% of adenocarcinomas.
|
16733863 |
2006 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase-2 (COX-2) is overexpressed in lung cancer, especially in adenocarcinoma (ADC).
|
16786043 |
2006 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
RGD |
COX-2 may play an important role in esophageal carcinogenesis through the activation of the inflammation-metaplasia-adenocarcinoma sequence.
|
17675820 |
2007 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
COX-2, the inducible isoenzyme, was found to be overexpressed in approximately 85% of colorectal adenocarcinomas, contributing to key steps in tumor development.
|
20075740 |
2010 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A.
|
9703885 |
1998 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
A longitudinal case-control study compared COX-2 in patients who progressed to adenocarcinoma with nonprogressors matched for age and length of follow-up.
|
15269153 |
2004 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
After stratification by disease stage or histologic subtype, the prognostic significance of high total COX-2 mRNA expression was still apparent in both stage I and stage II-IV and in both squamous cell carcinoma and adenocarcinoma (p < or = 0.01 for all).
|
15704107 |
2005 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Aspirin could down-regulate the strong expression of cyclooxygenase-2 in the tissue of gastric adenocarcinomas of nude mice.
|
12781040 |
2003 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Because our previous studies have indicated a significantly increased COX-2 expression in up to 70% of adenocarcinoma cases, the present findings are of great clinical interest.
|
10815926 |
2000 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
BEFREE |
Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.
|
11494020 |
2001 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.
|
12679908 |
2003 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
COX-1 and COX-2 expression in adenocarcinoma cell lines was determined using reverse transcription-PCR and Western blotting for mRNA and protein, respectively.
|
11059772 |
2000 |
|
Adenocarcinoma
|
0.600 |
Biomarker
|
group |
LHGDN |
COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.
|
17581270 |
2007 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase (COX)-2 appears to play an important role in gastrointestinal carcinogenesis, and COX-2 overexpression has been demonstrated both in esophageal adenocarcinomas and lymph nodes metastasis.
|
18443952 |
2008 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.
|
8566864 |
1996 |
|
Adenocarcinoma
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
|
18349295 |
2008 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
|
14744769 |
2004 |
|
Adenocarcinoma
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Differences between the levels of expression of COX-2 in primary tumors and their corresponding metastatic lymph nodes in 9 adenocarcinoma patients were not significant.
|
10665651 |
1999 |